Stefania Bonaccorso
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Stefania Bonaccorso has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Fabrizio Schifano
Psychopharmacology, Drug Misuse, and Novel Psychoactive Substances Research Unit, University of Hertfordshire, College Lane Campus, Hatfield AL10 9AB, UK
6 shared publications - Amira Guirguis
Pharmacy, Medical School, Swansea University, Swansea SA2 8PP, UK
4 shared publications - John Martin Corkery
Psychopharmacology, Drug Misuse, and Novel Psychoactive Substances Research Unit, University of Hertfordshire, College Lane Campus, Hatfield AL10 9AB, UK
4 shared publications - Angelo Ricciardi
North London NHS Foundation Trust, St Pancras Hospital, Pancras Road, London NW1 0PE, UK
3 shared publications - Norbert Scherbaum
LVR-University Hospital Essen, Department of Psychiatry and Psychotherapy, Medical Faculty, University of Duisburg-Essen, Essen, Germany
3 shared publications - Stefania Chiappini
School of Medicine, UniCamillus University, Via di S. Alessandro 8, 00131 Rome, Italy
3 shared publications
Latest Publications
- Open Access
- 24 November 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (12) , 1259
Managing Dual Diagnosis Patients and the Importance of Assessing Capacity: Data from London Inpatient Services
Objective: Substance use in patients with mental disorders is often associated with worse outcomes, increased risks, and impaired decision-making. Therefore, the evaluation of mental capacity in patients with coexisting mental illness and substance use disorder (dual diagnosis) is necessary to improve clinical outcomes and mitigate risks to self and others. Design: A retrospective inspection of electronic records for patients admitted between March 2017 and August 2020 in two London inpatient facilities was conducted. Capacity was assessed using the principles set out in the Mental Capacity Act 2005. Results: A capacity assessment was recorded in 34.9% of admissions. Only 6.2% of admissions whose primary diagnosis was mental and behavioral changes due to the use of substances had a recorded mental capacity assessment. Capacity to understand the negative impact of substances was assessed in 2.1% of total admissions. Conclusions: This study indicates very low rates of mental capacity assessment across acute psychiatric admissions, with very few relating to capacity to understand the risks associated with using substances. Further research on the capacity of patients with dual diagnosis is needed. This may help to manage certain risks in this patient population.
- 24 November 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (12) , 1259
Open AccessManaging Dual Diagnosis Patients and the Importance of Assessing Capacity: Data from London Inpatient Services
Objective: Substance use in patients with mental disorders is often associated with worse outcomes, increased risks, and impaired decision-making. Therefore, the evaluation of mental capacity in patients with coexisting mental illness and substance use disorder (dual diagnosis) is necessary to improve clinical outcomes and mitigate risks to self and others. Design: A retrospective inspection of electronic records for patients admitted between March 2017 and August 2020 in two London inpatient facilities was conducted. Capacity was assessed using the principles set out in the Mental Capacity Act 2005. Results: A capacity assessment was recorded in 34.9% of admissions. Only 6.2% of admissions whose primary diagnosis was mental and behavioral changes due to the use of substances had a recorded mental capacity assessment. Capacity to understand the negative impact of substances was assessed in 2.1% of total admissions. Conclusions: This study indicates very low rates of mental capacity assessment across acute psychiatric admissions, with very few relating to capacity to understand the risks associated with using substances. Further research on the capacity of patients with dual diagnosis is needed. This may help to manage certain risks in this patient population.
- Open Access
Focus on Cognitive Enhancement: A Narrative Overview of Nootropics and “Smart Drug” Use and Misuse
Whilst “nootropics” are meant to treat a range of medical disorder-related cognitive impairments, the typically healthy “smart drugs” user ingests a range of drugs/molecules to achieve improved mental performance. Given the increasing levels of related concerns, this study aimed to provide an overview of the clinical pharmacological issues relating to both the most popular nootropics and the vast range of drugs that are being used as putative cognitive enhancers/smart drugs. In terms of the cognitive decline associated with neurological degenerative disorders, a significant variation in research methodology was observed. Therefore, the overall usefulness of these pharmaceuticals in various central nervous system disorders as supplements/adjuvant therapy needs to be better established before their widespread use can be recommended. The most popular smart drugs, self-administered to cope with high-perceived stress and academic/work-related pressure, were methylphenidate, modafinil, amphetamine-based compounds, and psychedelics. At present, however, there are relevant levels of uncertainty in terms of smart drugs’ effectiveness in improving executive functions. Addressing the health harms associated with cognitive enhancers’ intake remains challenging due to the lack of updated and contextualized epidemiological data. In particular, there appears to be a range of clinical concerns relating to the non-prescribed intake of stimulant smart drugs by otherwise healthy individuals. Enhanced training for prescribers, pharmacists, and healthcare professionals can strengthen monitoring and early intervention efforts.
Open AccessFocus on Cognitive Enhancement: A Narrative Overview of Nootropics and “Smart Drug” Use and Misuse
Whilst “nootropics” are meant to treat a range of medical disorder-related cognitive impairments, the typically healthy “smart drugs” user ingests a range of drugs/molecules to achieve improved mental performance. Given the increasing levels of related concerns, this study aimed to provide an overview of the clinical pharmacological issues relating to both the most popular nootropics and the vast range of drugs that are being used as putative cognitive enhancers/smart drugs. In terms of the cognitive decline associated with neurological degenerative disorders, a significant variation in research methodology was observed. Therefore, the overall usefulness of these pharmaceuticals in various central nervous system disorders as supplements/adjuvant therapy needs to be better established before their widespread use can be recommended. The most popular smart drugs, self-administered to cope with high-perceived stress and academic/work-related pressure, were methylphenidate, modafinil, amphetamine-based compounds, and psychedelics. At present, however, there are relevant levels of uncertainty in terms of smart drugs’ effectiveness in improving executive functions. Addressing the health harms associated with cognitive enhancers’ intake remains challenging due to the lack of updated and contextualized epidemiological data. In particular, there appears to be a range of clinical concerns relating to the non-prescribed intake of stimulant smart drugs by otherwise healthy individuals. Enhanced training for prescribers, pharmacists, and healthcare professionals can strengthen monitoring and early intervention efforts.
- Open Access
- 22 April 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (5) , 424
Drugs Used in “Chemsex”/Sexualized Drug Behaviour—Overview of the Related Clinical Psychopharmacological Issues
Background: “Chemsex” involves the intake of a range of drugs (e.g., synthetic cathinones, gamma-hydroxybutyric acid/gamma-butyrolactone (GHB/GBL), ketamine, methamphetamine, “poppers”, type V phosphodiesterase (PDE) inhibitors, MDMA/ecstasy, cocaine, cannabis, and occasionally a few other molecules as well, to enhance and prolong sexual experiences. This paper aims to provide an overview of the clinical pharmacology of the vast range of drugs that are being used for chemsex with a focus on both the medical and psychopathological disturbances that they can produce. Methods: A narrative literature review was conducted using Pubmed, Scopus, and Web of Science databases. A total of 273 papers published up to January 2025 were screened; articles were selected based on relevance to chemsex/sexualized used behaviour and related substances. Both human and preclinical studies were considered. Results: The use of stimulants is likely related to the need to increase as much as possible both sexual arousal and performance but also to increase social interactions. Furthermore, the empathogenic/entactogenic activities of some MDMA-like “love drugs” facilitate the occurrence of “feeling closer/more intimate” emotional sensations, and GHB/GBL may provide the user with a subjective sensation of disinhibition, hence facilitating condomless meetings with a higher number of random partners. Conversely, ketamine may be used to both enjoy its psychotropic dissociative characteristics and facilitate the potentially painful receptive anal intercourse and/or fisting experiences. Most typically, these drugs are consumed in combination, with polydrug exposure possibly facilitating the occurrence of serotonergic syndrome, seizures, drug–drug pharmacokinetics’ interaction, and sympathomimetic overstimulation. Following these polydrug exposures, a range of psychopathological conditions have at times been reported. These issues may lead to misuse of opiates/opioids, gabapentinoids, and/or antipsychotics. Conclusions: Further actions should aim at reducing the stigma that prevents individuals from accessing necessary healthcare and support services. A multidisciplinary approach that combines medical, psychological, and social support remains key to managing the complex challenges posed by chemsex-related drug use.
- 22 April 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (5) , 424
Open AccessDrugs Used in “Chemsex”/Sexualized Drug Behaviour—Overview of the Related Clinical Psychopharmacological Issues
Background: “Chemsex” involves the intake of a range of drugs (e.g., synthetic cathinones, gamma-hydroxybutyric acid/gamma-butyrolactone (GHB/GBL), ketamine, methamphetamine, “poppers”, type V phosphodiesterase (PDE) inhibitors, MDMA/ecstasy, cocaine, cannabis, and occasionally a few other molecules as well, to enhance and prolong sexual experiences. This paper aims to provide an overview of the clinical pharmacology of the vast range of drugs that are being used for chemsex with a focus on both the medical and psychopathological disturbances that they can produce. Methods: A narrative literature review was conducted using Pubmed, Scopus, and Web of Science databases. A total of 273 papers published up to January 2025 were screened; articles were selected based on relevance to chemsex/sexualized used behaviour and related substances. Both human and preclinical studies were considered. Results: The use of stimulants is likely related to the need to increase as much as possible both sexual arousal and performance but also to increase social interactions. Furthermore, the empathogenic/entactogenic activities of some MDMA-like “love drugs” facilitate the occurrence of “feeling closer/more intimate” emotional sensations, and GHB/GBL may provide the user with a subjective sensation of disinhibition, hence facilitating condomless meetings with a higher number of random partners. Conversely, ketamine may be used to both enjoy its psychotropic dissociative characteristics and facilitate the potentially painful receptive anal intercourse and/or fisting experiences. Most typically, these drugs are consumed in combination, with polydrug exposure possibly facilitating the occurrence of serotonergic syndrome, seizures, drug–drug pharmacokinetics’ interaction, and sympathomimetic overstimulation. Following these polydrug exposures, a range of psychopathological conditions have at times been reported. These issues may lead to misuse of opiates/opioids, gabapentinoids, and/or antipsychotics. Conclusions: Further actions should aim at reducing the stigma that prevents individuals from accessing necessary healthcare and support services. A multidisciplinary approach that combines medical, psychological, and social support remains key to managing the complex challenges posed by chemsex-related drug use.
- 1 September 2019
- Published by Elsevier in NeuroToxicology
- Vol. 74, 282-298
Cannabidiol (CBD) use in psychiatric disorders: A systematic review
- 1 September 2019
- Published by Elsevier in NeuroToxicology
- Vol. 74, 282-298
Cannabidiol (CBD) use in psychiatric disorders: A systematic review
- Open Access
- 7 May 2019
- Published by Springer Nature in Current Addiction Reports
- Vol. 6 (2) , 153-154
Correction to: New Psychoactive Substances (NPS), Psychedelic Experiences and Dissociation: Clinical and Clinical Pharmacological Issues
- 7 May 2019
- Published by Springer Nature in Current Addiction Reports
- Vol. 6 (2) , 153-154
Open AccessCorrection to: New Psychoactive Substances (NPS), Psychedelic Experiences and Dissociation: Clinical and Clinical Pharmacological Issues
- 23 April 2019
- Published by Springer Nature in Current Addiction Reports
- Vol. 6 (2) , 140-152
New Psychoactive Substances (NPS), Psychedelic Experiences and Dissociation: Clinical and Clinical Pharmacological Issues
- 23 April 2019
- Published by Springer Nature in Current Addiction Reports
- Vol. 6 (2) , 140-152
New Psychoactive Substances (NPS), Psychedelic Experiences and Dissociation: Clinical and Clinical Pharmacological Issues
- Open Access
- 14 July 2018
- Published by MDPI AG in Brain Sciences
- Vol. 8 (7) , 133
Synthetic Cannabinoid use in a Case Series of Patients with Psychosis Presenting to Acute Psychiatric Settings: Clinical Presentation and Management Issues
Background: Novel Psychoactive Substances (NPS) are a heterogeneous class of synthetic molecules including synthetic cannabinoid receptor agonists (SCRAs). Psychosis is associated with SCRAs use. There is limited knowledge regarding the structured assessment and psychometric evaluation of clinical presentations, analytical toxicology and clinical management plans of patients presenting with psychosis and SCRAs misuse. Methods: We gathered information regarding the clinical presentations, toxicology and care plans of patients with psychosis and SCRAs misuse admitted to inpatients services. Clinical presentations were assessed using the PANSS scale. Vital signs data were collected using the National Early Warning Signs tool. Analytic chemistry data were collected using urine drug screening tests for traditional psychoactive substances and NPS. Results: We described the clinical presentation and management plan of four patients with psychosis and misuse of SCRAs. Conclusion: The formulation of an informed clinical management plan requires a structured assessment, identification of the index NPS, pharmacological interventions, increases in nursing observations, changes to leave status and monitoring of the vital signs. The objective from using these interventions is to maintain stable physical health whilst rapidly improving the altered mental state.
- 14 July 2018
- Published by MDPI AG in Brain Sciences
- Vol. 8 (7) , 133
Open AccessSynthetic Cannabinoid use in a Case Series of Patients with Psychosis Presenting to Acute Psychiatric Settings: Clinical Presentation and Management Issues
Background: Novel Psychoactive Substances (NPS) are a heterogeneous class of synthetic molecules including synthetic cannabinoid receptor agonists (SCRAs). Psychosis is associated with SCRAs use. There is limited knowledge regarding the structured assessment and psychometric evaluation of clinical presentations, analytical toxicology and clinical management plans of patients presenting with psychosis and SCRAs misuse. Methods: We gathered information regarding the clinical presentations, toxicology and care plans of patients with psychosis and SCRAs misuse admitted to inpatients services. Clinical presentations were assessed using the PANSS scale. Vital signs data were collected using the National Early Warning Signs tool. Analytic chemistry data were collected using urine drug screening tests for traditional psychoactive substances and NPS. Results: We described the clinical presentation and management plan of four patients with psychosis and misuse of SCRAs. Conclusion: The formulation of an informed clinical management plan requires a structured assessment, identification of the index NPS, pharmacological interventions, increases in nursing observations, changes to leave status and monitoring of the vital signs. The objective from using these interventions is to maintain stable physical health whilst rapidly improving the altered mental state.
- Open Access
- 1 May 2017
- Published by Cambridge University Press (CUP) in European Psychiatry
- Vol. 42, 1-7
Sexual dysfunction and central obesity in patients with first episode psychosis
Background: In recent years the association between sexual dysfunction (SD) and obesity in the general population has drawn major attention. Although sexual dysfunction is common in psychosis, its relationship with weight gain and obesity remains unclear.Aims: To investigate the association between sexual dysfunction and obesity in a cohort of patients with first episode psychosis.Method: Sexual function was assessed in a cohort of patients with first episode psychosis using the Sexual Function Questionnaire (SFQ). Anthropometric measures, including weight, BMI, waist, waist–hip ratio were investigated. Additionally, leptin and testosterone were investigated in male patients.Results: A total of 116 patients (61 males and 55 females) were included. Of these 59% of males and 67.3% of females showed sexual dysfunction (SD) according to the SFQ. In males, higher SFQ scores were significantly correlated with higher BMI (Std. β = 0.36,P= 0.01), higher leptin levels (Std. β = 0.34,P= 0.02), higher waist–hip ratio (Std. β = 0.32,P= 0.04) and lower testosterone levels (Std. β = −0.44,P= 0.002). In contrast, in females, SFQ scores were not associated with any of these factors.Conclusions: While sexual dysfunction is present in both female and male patients with their first episode of psychosis, only in males is sexual dysfunction associated with increased BMI and waist–hip ratio. The association between SD, BMI, low levels of testosterone and high levels of leptin suggest that policies that lead to healthier diets and more active lifestyles can be beneficial at least, to male patients.
- 1 May 2017
- Published by Cambridge University Press (CUP) in European Psychiatry
- Vol. 42, 1-7
Open AccessSexual dysfunction and central obesity in patients with first episode psychosis
Background: In recent years the association between sexual dysfunction (SD) and obesity in the general population has drawn major attention. Although sexual dysfunction is common in psychosis, its relationship with weight gain and obesity remains unclear.Aims: To investigate the association between sexual dysfunction and obesity in a cohort of patients with first episode psychosis.Method: Sexual function was assessed in a cohort of patients with first episode psychosis using the Sexual Function Questionnaire (SFQ). Anthropometric measures, including weight, BMI, waist, waist–hip ratio were investigated. Additionally, leptin and testosterone were investigated in male patients.Results: A total of 116 patients (61 males and 55 females) were included. Of these 59% of males and 67.3% of females showed sexual dysfunction (SD) according to the SFQ. In males, higher SFQ scores were significantly correlated with higher BMI (Std. β = 0.36,P= 0.01), higher leptin levels (Std. β = 0.34,P= 0.02), higher waist–hip ratio (Std. β = 0.32,P= 0.04) and lower testosterone levels (Std. β = −0.44,P= 0.002). In contrast, in females, SFQ scores were not associated with any of these factors.Conclusions: While sexual dysfunction is present in both female and male patients with their first episode of psychosis, only in males is sexual dysfunction associated with increased BMI and waist–hip ratio. The association between SD, BMI, low levels of testosterone and high levels of leptin suggest that policies that lead to healthier diets and more active lifestyles can be beneficial at least, to male patients.
- 15 April 2015
- Published by Wiley in Bipolar Disorders
- Vol. 17 (5) , 528-535
The brain‐derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia
Objectives: We tested the hypothesis that a common functional variant in brain‐derived neurotrophic factor (BDNF), Val66Met, which has been shown to be associated with increased body mass index (BMI) in schizophrenia (SCZ) and schizoaffective disorder (SAD), is also associated with antipsychotic‐induced weight gain in bipolar disorder (BPD). Association of Val66Met with other metabolic measures, including high‐ and low‐density cholesterol, triglycerides, total cholesterol, fasting blood glucose, and hemoglobin A1c, was also tested.Methods: This was a 12‐month, prospective, randomized trial of two atypical antipsychotic drugs (APDs) with moderate (risperidone) or high (olanzapine) risk to cause weight gain. Subjects were diagnosed as having BPD (n = 90) and SCZ or SAD (n = 76).Results: BMI was significantly greater in all diagnoses for Met66 allele carriers at six months (p = 0.01). Met66 carriers with BPD showed a greater increase in the triglycerides/high‐density (HDL) cholesterol ratio (p = 0.01), a key marker for metabolic syndrome related to insulin resistance, and log‐triglycerides (p = 0.04), after three or six months of treatment. Met66 carriers had the greatest increase in log‐triglycerides (p = 0.03) and triglycerides/HDL cholesterol ratio after three months of treatment with risperidone (p = 0.003), and the highest BMI at six months (p = 0.01).Conclusions: The positive association of BNDF Val66Met with high BMI values replicates previous findings in patients with SCZ and indicates the BDNF Val66Met genotype as a potential risk factor for obesity and insulin resistance measures in patients with BPD receiving antipsychotics as well.
- 15 April 2015
- Published by Wiley in Bipolar Disorders
- Vol. 17 (5) , 528-535
The brain‐derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia
Objectives: We tested the hypothesis that a common functional variant in brain‐derived neurotrophic factor (BDNF), Val66Met, which has been shown to be associated with increased body mass index (BMI) in schizophrenia (SCZ) and schizoaffective disorder (SAD), is also associated with antipsychotic‐induced weight gain in bipolar disorder (BPD). Association of Val66Met with other metabolic measures, including high‐ and low‐density cholesterol, triglycerides, total cholesterol, fasting blood glucose, and hemoglobin A1c, was also tested.Methods: This was a 12‐month, prospective, randomized trial of two atypical antipsychotic drugs (APDs) with moderate (risperidone) or high (olanzapine) risk to cause weight gain. Subjects were diagnosed as having BPD (n = 90) and SCZ or SAD (n = 76).Results: BMI was significantly greater in all diagnoses for Met66 allele carriers at six months (p = 0.01). Met66 carriers with BPD showed a greater increase in the triglycerides/high‐density (HDL) cholesterol ratio (p = 0.01), a key marker for metabolic syndrome related to insulin resistance, and log‐triglycerides (p = 0.04), after three or six months of treatment. Met66 carriers had the greatest increase in log‐triglycerides (p = 0.03) and triglycerides/HDL cholesterol ratio after three months of treatment with risperidone (p = 0.003), and the highest BMI at six months (p = 0.01).Conclusions: The positive association of BNDF Val66Met with high BMI values replicates previous findings in patients with SCZ and indicates the BDNF Val66Met genotype as a potential risk factor for obesity and insulin resistance measures in patients with BPD receiving antipsychotics as well.
- 1 October 2014
- Published by Elsevier in Schizophrenia Research
- Vol. 159 (1) , 56-61
Brain derived neurotropic factor (BDNF) is associated with childhood abuse but not cognitive domains in first episode psychosis
- 1 October 2014
- Published by Elsevier in Schizophrenia Research
- Vol. 159 (1) , 56-61
Brain derived neurotropic factor (BDNF) is associated with childhood abuse but not cognitive domains in first episode psychosis